Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 7 |
List of Tables | 7 | 1 |
List of Figures | 8 | 1 |
Introduction | 9 | 1 |
Global Markets Direct Report Coverage | 9 | 1 |
Aspergillosis Overview | 10 | 1 |
Therapeutics Development | 11 | 2 |
Pipeline Products for Aspergillosis Overview | 11 | 1 |
Pipeline Products for Aspergillosis Comparative Analysis | 12 | 1 |
Aspergillosis Therapeutics under Development by Companies | 13 | 2 |
Aspergillosis Therapeutics under Investigation by Universities/Institutes | 15 | 1 |
Aspergillosis Pipeline Products Glance | 16 | 4 |
Late Stage Products | 16 | 1 |
Clinical Stage Products | 17 | 1 |
Early Stage Products | 18 | 1 |
Unknown Stage Products | 19 | 1 |
Aspergillosis Products under Development by Companies | 20 | 1 |
Aspergillosis Products under Investigation by Universities/Institutes | 21 | 1 |
Aspergillosis Companies Involved in Therapeutics Development | 22 | 19 |
Amplyx Pharmaceuticals, Inc. | 22 | 1 |
Astellas Pharma Inc. | 23 | 1 |
Biomar Microbial Technologies | 24 | 1 |
Biosergen AS | 25 | 1 |
Cidara Therapeutics, Inc. | 26 | 1 |
F2G Ltd | 27 | 1 |
Hsiri Therapeutics LLC | 28 | 1 |
iCo Therapeutics Inc. | 29 | 1 |
Matinas BioPharma Holdings, Inc. | 30 | 1 |
Merck &Co., Inc. | 31 | 1 |
Nanomerics Ltd | 32 | 1 |
Novabiotics Limited | 33 | 1 |
Pulmatrix, Inc. | 34 | 1 |
Pulmocide Ltd | 35 | 1 |
Scynexis, Inc. | 36 | 1 |
Sealife PHARMA GMBH | 37 | 1 |
Sigma-Tau S.p.A. | 38 | 1 |
TGV-Laboratories | 39 | 1 |
Vical Incorporated | 40 | 1 |
Aspergillosis Therapeutics Assessment | 41 | 9 |
Assessment by Monotherapy Products | 41 | 1 |
Assessment by Target | 42 | 2 |
Assessment by Mechanism of Action | 44 | 2 |
Assessment by Route of Administration | 46 | 2 |
Assessment by Molecule Type | 48 | 2 |
Drug Profiles | 50 | 44 |
amphotericin B Drug Profile | 50 | 2 |
amphotericin B Drug Profile | 52 | 1 |
amphotericin B Drug Profile | 53 | 3 |
amphotericin B Drug Profile | 56 | 1 |
Amphotericin B sodium Drug Profile | 57 | 2 |
APX-001 Drug Profile | 59 | 2 |
ASP-9726 Drug Profile | 61 | 1 |
Aspergillus fumigatus vaccine Drug Profile | 62 | 1 |
BSG-005 Drug Profile | 63 | 1 |
C-001 Drug Profile | 64 | 1 |
C-016 Drug Profile | 65 | 1 |
celastrol Drug Profile | 66 | 1 |
Cellullar Immunotherapy for Viral Infections and Fungal Infections Drug Profile | 67 | 1 |
F-901318 Drug Profile | 68 | 2 |
itraconazole Drug Profile | 70 | 2 |
KB-425796C Drug Profile | 72 | 1 |
MDN-0018 Drug Profile | 73 | 1 |
Myc-102 Drug Profile | 74 | 1 |
NP-339 Drug Profile | 75 | 1 |
NP-525 Drug Profile | 76 | 1 |
PC-945 Drug Profile | 77 | 1 |
posaconazole Drug Profile | 78 | 2 |
PTX-3 Drug Profile | 80 | 1 |
SCY-078 Drug Profile | 81 | 4 |
SLP-0901 Drug Profile | 85 | 1 |
SLP-0904 Drug Profile | 86 | 1 |
Small Molecule for Aspergillosis Drug Profile | 87 | 1 |
Small Molecules for Aspergillosis and Candidiasis Drug Profile | 88 | 1 |
Small Molecules for Fungal Infections Drug Profile | 89 | 1 |
Small Molecules for Fungal Infections Drug Profile | 90 | 1 |
Small Molecules for Invasive Aspergillosis Drug Profile | 91 | 1 |
Vaccine for Fungal Infections Drug Profile | 92 | 1 |
VL-2397 Drug Profile | 93 | 1 |
Aspergillosis Dormant Projects | 94 | 1 |
Aspergillosis Discontinued Products | 95 | 1 |
Aspergillosis Product Development Milestones | 96 | 11 |
Featured News &Press Releases | 96 | 1 |
Oct 26, 2016: F2G Announces Publication of Initial F901318 Data in Scientific Journal PNAS | 96 | 1 |
Sep 12, 2016: Amplyx Pharmaceuticals Initiates Dosing in Phase 1 Clinical Trial of APX001, a Novel Antifungal Product Candidate for Treatment of Life-Threatening Infections | 96 | 1 |
Aug 24, 2016: SCYNEXIS Receives Orphan Drug Designation for SCY-078 for the Treatment of Invasive Aspergillus Infections | 97 | 1 |
Jun 16, 2016: Antifungal work lands SBU professor $6 million from NIH | 97 | 2 |
Jun 14, 2016: Amplyx Pharmaceuticals Announces Qualified Infectious Disease Product Designation for APX001 in Three Life-threatening Fungal Infections | 99 | 1 |
May 24, 2016: Amplyx Pharmaceuticals Appoints Paul C. Grint, M.D., to Board of Directors | 100 | 1 |
Mar 30, 2016: FDA Grants Vical Fast Track Designation for VL-2397 for the Treatment of Invasive Aspergillosis | 100 | 1 |
Mar 07, 2016: Vical Initiates Phase 1 Trial of Novel Antifungal Compound VL-2397 | 101 | 1 |
Jan 28, 2016: SCYNEXIS Receives FDA Fast Track and QIDP Designations for Intravenous Formulation of SCY-078 for the Treatment of Patients with Invasive Fungal Infections | 101 | 1 |
Jan 06, 2016: FDA Grants Vical Orphan Drug Designation for VL-2397 for the Treatment of Invasive Aspergillosis | 102 | 1 |
Dec 17, 2015: Matinas BioPharma s Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations for Treatment of Aspergillus by U.S. FDA | 103 | 1 |
Nov 30, 2015: F2G to Participate in the Adaptive Pathways Pilot Programme | 103 | 1 |
Sep 21, 2015: SCYNEXIS Presents Data Supporting the Potential Clinical Utility of Antifungal Drug Candidate at ICAAC/ICC 2015 | 104 | 1 |
Sep 15, 2015: Vical to Present Preclinical Data at ICAAC 2015 Meeting for Its Novel Antifungal Drug Candidate VL-2397 | 105 | 1 |
Aug 19, 2015: FDA Grants Qualified Infectious Disease Product Designation to VL-2397, Vical's Antifungal Product Candidate | 105 | 2 |
Appendix | 107 | 2 |
Methodology | 107 | 1 |
Coverage | 107 | 1 |
Secondary Research | 107 | 1 |
Primary Research | 107 | 1 |
Expert Panel Validation | 107 | 1 |
Contact Us | 107 | 1 |
Disclaimer | 108 | 1 |